FENNEC PHARMACEUTICALS INITIATES ROLLING NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARK™

PEDMARKTM is proposed to be indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic, solid tumors. Research Triangle Park, NC, December 20, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, following a pre-submission meeting with the oncology […]

FENNEC PHARMACEUTICALS ANNOUNCES SCIENTIFIC SYMPOSIUM ON OTOTOXICITY IN PEDIATRIC CANCER PATIENTS AT THE 50TH CONGRESS OF THE INTERNATIONAL SOCIETY OF PEDIATRIC ONCOLOGY (SIOP) 2018 MEETING

Research Triangle Park, NC, November 16, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that leading experts in pediatric oncology will review the current data and clinical […]

Fennec Provides Business Update and Announces Third Quarter 2018 Financial Results

Positive Opinion on the Pediatric Investigation Plan from EMA for PEDMARKTM Targeting US approval of PEDMARKTM in the second half of 2019 Strong financial position with $24.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the […]

Fennec to Present at Cantor Fitzgerald Global Healthcare Conference on October 1, 2018 in New York City

Research Triangle Park, NC, September 26, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that Rosty Raykov, CEO of Fennec, will present a corporate overview at the […]

SEPTEMBER 13 MEETING WILL EXPLORE CHEMO-INDUCED HEARING LOSS IN PEDIATRICS

WASHINGTON, DC — Young adult survivors of childhood cancer and parents of children with cancer are invited to participate via webcast in a workshop on Chemotherapy-Induced Hearing Loss in Pediatrics, taking place in the DC metro area on September 13, 2018. This half-day event follows the Food and Drug Administration’s (FDA) model for externally-led Patient […]

Fennec Provides Business Update and Announces Second Quarter 2018 Financial Results

Publication of PEDMARKTM SIOPEL 6 Clinical Data in The New England Journal of Medicine Joined Russell 3000 Index Strong financial position with $25.6 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique […]

FENNEC PHARMACEUTICALS RECEIVES POSITIVE OPINION ON THE PEDIATRIC INVESTIGATION PLAN FROM EUROPEAN MEDICINES AGENCY FOR PEDMARKTM AND CONFIRMATION OF ELIGIBILITY FOR A PEDIATRIC USE MARKETING AUTHORIZATION

Research Triangle Park, NC, August 7, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the Company’s pediatric investigation plan (PIP) for PEDMARKTM for the condition of the prevention of platinum-induced ototoxic hearing loss. The indication targeted […]

Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine

SIOPEL 6 met primary endpoint (p=0.002) 48% reduction in the incidence of hearing loss No evidence of tumor protection RESEARCH TRIANGLE PARK, N.C., June 21, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)), announced today a publication in […]

Fennec Pharmaceuticals Set to Join Russell 3000 Index

Research Triangle Park, NC, June 11, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC, TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today it is set to join the broad-market Russell 3000Ò Index at the […]

Fennec Announces Results of Annual Meeting

Research Triangle Park, NC — (Marketwired) – June 7, 2018– Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 30, 2018 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General and […]

Fennec Provides Business Update and Announces First Quarter 2018 Financial Results

PEDMARKTM granted Breakthrough Therapy and Fast Track Designations by FDA Actively preparing for NDA submission later this year Strong financial position with $26.7 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., May 14, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation […]

FENNEC PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR PEDMARK™

Research Triangle Park, NC, March 27, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted PEDMARK™ (a unique formulation of sodium thiosulfate) Breakthrough Therapy designation for prevention of cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma (SR-HB). “The decision […]

FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2017 FINANCIAL RESULTS

Phase 3 SIOPEL 6 study met primary endpoint (p=0.0033) NASDAQ listing in September 2017 Two equity financings completed Strong financial position at year end with $28.3 million in cash and no debt  Research Triangle Park, NC, March 26, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of […]

FENNEC PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION BY FDA FOR PEDMARK

Research Triangle Park, NC, March 21, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted PEDMARK (a unique formulation of sodium thiosulfate) Fast Track designation for prevention of cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma (SR-HB). There are […]